RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced the selection of opaganib1, a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor being evaluated for the treatment of severe COVID-19 pneumonia, to receive a $300,000 grant from the State of Pennsylvania’s COVID-19 Vaccines, Treatments and Therapies (CV-VTT) Program, which is designed to support rapid advancement of novel COVID-19 therapies. The grant was awarded to RedHill’s partner, Apogee Biotechnology Corporation, from whom RedHill licensed opaganib, who will conduct the research being supported by the grant.
Glucose is central to life, and errors in glucose metabolism are found in many diseases. Cayman has developed an array of reagents and tools for researchers studying those diseases.nCayman offers kits for measuring insulin (Insulin (rat) EIA Kit) and glucose (Glucose Colorimetric Assay Kit) as well as a cell-based assay kit for measuring glucose uptake (Glucose Uptake Cell-Based Assay Kit). Also, we offer high-purity reagents that regulate insulin-mediated cell-signaling and the action of glucose transporters.